CIK 0001764013 · Large accelerated filer
Immunovant, Inc.
Sign in to watch- Ticker
- IMVT
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Mar 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 832771572
- Phone
- 917-410-3120
- Business address
- 1000 PARK FORTY PLAZA, DURHAM, NC, 27713
- Former names
- Health Sciences Acquisitions Corp
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $1,030,805
- in 10 filings, $173K under 10b5-1 plans
Net −$1,030,805. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-11-11 | Pande Atul Director | Option exercise 10b5-1 | +3,000 | $8.43 | $25K | 119,731 |
| 2026-11-11 | Pande Atul Director | Sale 10b5-1 | −3,000 | $36.00 | $108K | 116,731 |
| 2026-11-11 | Pande Atul Director | Option exercise · Stock Option (right to buy) 10b5-1 | −3,000 | 62,181 | ||
| 2026-10-28 | Girao Tiago Chief Financial Officer | Sale | −6,606 | $28.50 | $188K | 234,192 |
| 2026-10-21 | Stout Jay S Chief Technology Officer | Sale | −2,595 | $28.94 | $75K | 198,937 |
| 2026-10-07 | Van Tuyl Christopher Chief Legal Officer | Sale | −1,327 | $32.06 | $43K | 175,218 |
| 2026-10-07 | Gloria Melanie Chief Operating Officer | Sale | −2,241 | $32.06 | $72K | 217,060 |
| 2026-10-07 | Stout Jay S Chief Technology Officer | Sale | −2,213 | $32.06 | $71K | 203,128 |
| 2026-10-07 | Stout Jay S Chief Technology Officer | Sale | −1,596 | $32.06 | $51K | 201,532 |
| 2026-10-02 | Venker Eric Chief Executive Officer | Sale | −3,506 | $34.11 | $120K | 257,075 |
| 2026-10-01 | Venker Eric Chief Executive Officer | Option exercise | +92,187 | $14.46 | $1.3M | 346,467 |
| 2026-10-01 | Venker Eric Chief Executive Officer | Returned to the company | −85,886 | $33.65 | $2.9M | 260,581 |
| 2026-10-01 | Venker Eric Chief Executive Officer | Option exercise · Capped Value Appreciation Rights | −92,187 | 921,875 | ||
| 2026-09-23 | Van Tuyl Christopher Chief Legal Officer | Sale | −2,846 | $36.36 | $103K | 176,545 |
| 2026-08-28 | Pande Atul Director | Option exercise 10b5-1 | +1,500 | $8.43 | $13K | 118,231 |
| 2026-08-28 | Pande Atul Director | Sale 10b5-1 | −1,500 | $43.27 | $65K | 116,731 |
| 2026-08-28 | Pande Atul Director | Option exercise · Stock Option (right to buy) 10b5-1 | −1,500 | 65,181 | ||
| 2026-08-20 | Gloria Melanie Chief Operating Officer | Sale | −3,056 | $44.16 | $135K | 219,301 |
| 2026-07-24 | Pande Atul Director | Option exercise 10b5-1 | +1,500 | $8.43 | $13K | 118,231 |
| 2026-07-24 | Pande Atul Director | Sale 10b5-1 | −1,500 | $39.80 | $60K | 116,731 |
Page 1 of 10 · 191 trades